IRVINE, CA, and HERSTAL, BELGIUM – March 29, 2016 – MDxHealth SA (Euronext: MDXH.BR), announced today that it has partnered with Andros Men’s Health Clinic (Andros Mannenkliniek) in The Netherlands to offer the SelectMDx(TM) for Prostate Cancer test to their patients.

Through this new partnership, Andros Men’s Clinic (Mannenkliniek), the largest independent urological treatment center in The Netherlands, has added SelectMDx to its panel of men’s prostate cancer diagnostic tests. The SelectMDx is a non-invasive urine based test to identify men at risk for aggressive prostate cancer who may benefit from early detection and an initial prostate biopsy or magnetic resonance imaging (MRI). A negative SelectMDx also helps identify men at very low risk for clinically significant cancer, and could reduce unnecessary invasive biopsies, thereby reducing healthcare costs.

Under this partnership the Andros Men’s Health Clinic will offer the SelectMDx test to all patients considered at risk for prostate cancer and over 500 patients to undergo testing in the first year alone. The SelectMDx test will be available to Andros Men’s Health Clinic patients starting on April 1st 2016.

Prof. Dr. Frans Debruyne, Medical Director and Co-Founder of the Andros Men’s Health Clinic (Andros Mannenkliniek) stated: “At our clinic we recently launched a program we call the Andros Center for Prostate Cancer to deliver precision diagnosis for prostate cancer. Through this program we offer innovative diagnostic technologies (including mpMRI) to improve the diagnosis of aggressive prostate cancer and prescribe the optimal treatment plan for our patients. Now we have further enhanced our diagnostic algorithm with the SelectMDx test, which is indicated for men with high risk factors such as abnormal DRE and/or elevated PSA levels who are being considered for prostate biopsy. We believe the test will aid in improved patient risk stratification, avoiding unnecessary biopsy procedures for low risk men, as well as identifying men at risk for clinically significant cancer who may require treatment.” 

“We are delighted to announce our collaboration with Andros Men’s Health Clinic, an established leader for aging men’s health care in The Netherlands; our SelectMDx test perfectly complements their portfolio of advanced diagnostic tools,” commented Dr. Jan Groen, CEO of MDxHealth. “They have built a strong reputation with a focus on improving patient care and outcomes, and therefore make an ideal partner to help us raise awareness and expand access to SelectMDx within the urology community.”

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company’s tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit and follow us on Twitter at:

About Andros Men’s Health Clinic (Andros Mannenkliniek)

Andros Men’s Health Clinic is the largest independent urological treatment center in The Netherlands with medical offices in Amsterdam, Arnhem, Baarn, The Hague and Maastricht. The specialized clinic focuses on the general urogenital health of ageing men and aims to address issues with the prostate, erectile dysfunction and hormone deficiencies. On an annual basis more over 6,000 men visited the Andros Clinic.

About SelectMDx for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDxTM for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive “liquid biopsy” method to assess a man’s risk for prostate cancer. SelectMDx helps identify men at increased risk of harbouring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce unnecessary MRI procedures and invasive prostate biopsies by approximately 50%, thereby reducing healthcare costs. 

For more information:


Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70  




Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: +1 917 322 2571 (Rx Communications Group LLC)


Frans M.J. Debruyne, MD, PhD
Professor of Urology (Em.)
Medical Director Andros Men’s Health Institutes
NL: +31 26 3891753


This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation.  This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.